Page 528 - Hematology_ Basic Principles and Practice ( PDFDrive )

444.e4 Part IV Disorders of Hematopoietic Cell Development

156. Davis KA, Finger DR, Shparago NI: Disseminated histoplasmosis 181. Kaufman DW, Kelly JP, Jurgelon JM, et al: Drugs in the aetiology of
mimicking Felty’s syndrome. J Clin Rheumatol 8:38, 2002. agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 60:23,
157. Zuger A: Profound neutropenia in an HIV-infected man. AIDS Clin 1996.
Care 8:67, 1996. 182. Blackburn SC, Oliart AD, Garcia Rodriguez LA, et al: Antiepileptics
158. Dale DC, Wolff SM: Studies of the neutropenia of acute malaria. Blood and blood dyscrasias: A cohort study. Pharmacotherapy 18:1277, 1998.
41:197, 1973. 183. Melenhorst JJ, Sorbara L, Kirby M, et al: Large granular lymphocyte
159. Thomssen C, Nissen C, Gratwohl A, et al: Agranulocytosis associated leukaemia is characterized by a clonal T-cell receptor rearrangement
with T-gamma-lymphocytosis: No improvement of peripheral blood in both memory and effector CD8(+) lymphocyte populations. Br J
granulocyte count with human-recombinant granulocyte-macrophage Haematol 112:189, 2001.
colony-stimulating factor (GM-CSF). Br J Haematol 71:157, 1989. 184. Garrido P, Ruiz-Cabello F, Barcena P, et al: Monoclonal TCR-
160. Martinez-Banos D, Crispin JC, Lazo-Langner A, et al: Moderate and Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis:
severe neutropenia in patients with systemic lupus erythematosus. Evidence for an antigen-driven chronic T-cell stimulation origin. Blood
Rheumatology (Oxford) 45:994, 2006. 109:4890, 2007.
161. Hellmich B, Schnabel A, Gross WL: Treatment of severe neutrope- 185. Ribichini F, Ferrero V, Feola M, et al: Neutropenia in patients treated
nia due to Felty’s syndrome or systemic lupus erythematosus with with thienopyridines and high-dose oral prednisone after percutaneous
granulocyte colony-stimulating factor. Semin Arthritis Rheum 29:82, coronary interventions. J Interv Cardiol 20:209, 2007.
1999. 186. Bjornson BH, McIntyre AP, Harvey JM, et al: Studies of the effects of
162. Hellmich B, Pinals RS, Loughran TP, Jr, et al: New clues to accrue on trimethoprim and sulfamethoxazole on human granulopoiesis. Am J
neutropenia in rheumatoid arthritis. Clin Immunol 117:1, 2005. Hematol 23:1, 1986.
163. Winkelstein JA, Marino MC, Lederman HM, et al: X-linked agam- 187. Kontoghiorghes GJ: Deferasirox: Uncertain future following renal
maglobulinemia: Report on a United States registry of 201 patients. failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug
Medicine (Baltimore) 85:193, 2006. Saf 6:235, 2007.
164. Cham B, Bonilla MA, Winkelstein J: Neutropenia associated with 188. Melenhorst JJ, Eniafe R, Follmann D, et al: T-cell large granular
primary immunodeficiency syndromes. Semin Hematol 39:107, lymphocyte leukemia is characterized by massive TCRBV-restricted
2002. clonal CD8 expansion and a generalized overexpression of the effector
165. Becton DL, Schultz WH, Kinney TR: Severe neutropenia caused by cell marker CD57. Hematol J 4:18, 2003.
copper deficiency in a child receiving continuous ambulatory peritoneal 189. Aymard JP, Aymard B, Netter P, et al: Haematological adverse effects
dialysis. J Pediatr 108:735, 1986. of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp
166. Zidar BL, Shadduck RK, Zeigler Z, et al: Observations on the anemia 3:430, 1988.
and neutropenia of human copper deficiency. Am J Hematol 3:177, 190. van der Klauw MM, Wilson JH, Stricker BH: Drug-associated agranu-
1977. locytosis: 20 years of reporting in The Netherlands (1974-1994). Am J
167. Stroncek DF, Keshaviah P, Craddock PR, et al: Effect of dialyzer reuse Hematol 57:206, 1998.
on complement activation and neutropenia in hemodialysis. J Lab Clin 191. Cormican LJ, Schey S, Milburn HJ: G-CSF enables completion of
Med 104:304, 1984. tuberculosis therapy associated with iatrogenic neutropenia. Eur Respir
168. Skubitz KM, Craddock PR: Reversal of hemodialysis granulocytopenia J 23:649, 2004.
and pulmonary leukostasis: A clinical manifestation of selective down- 192. Jenkins PF, Williams TD, Campbell IA: Neutropenia with each stan-
regulation of granulocyte responses to C5adesarg. J Clin Invest 67:1383, dard antituberculosis drug in the same patient. Br Med J 280:1069,
1981. 1980.
169. Palmblad JE, dem Borne AE: Idiopathic, immune, infectious, and 193. Tanaka M, Tao T, Kaku K, et al: Agranulocytosis induced by macrolide
idiosyncratic neutropenias. Semin Hematol 39:113, 2002. antibiotics. Am J Hematol 48:133, 1995.
170. Turbay D, Lieberman J, Alper CA, et al: Tumor necrosis factor constel- 194. Pastor E, Linares M, Grau E: Erythromycin-induced agranulocytosis.
lation polymorphism and clozapine-induced agranulocytosis in two DICP 25:1136, 1991.
different ethnic groups. Blood 89:4167, 1997. 195. Hennequin C, Bouree P, Halfon P: Agranulocytosis during treatment
171. Risks of agranulocytosis and aplastic anemia. A first report of their rela- with mefloquine. Lancet 337:984, 1991.
tion to drug use with special reference to analgesics. The International 196. Bonadonna A, Bisetto F, Munaretto G, et al: Agranulocytosis during
Agranulocytosis and Aplastic Anemia Study. JAMA 256:1749, 1986. nifedipine treatment in a hemodialysis patient. Nephron 47:306, 1987.
172. Kelly JP, Kaufman DW, Shapiro S: Risks of agranulocytosis and aplastic 197. Laurenson IF, Buckoke C, Davidson C, et al: Delayed fatal agranulocy-
anemia in relation to the use of cardiovascular drugs: The International tosis in an epileptic taking primidone and phenytoin. Lancet 344:332,
Agranulocytosis and Aplastic Anemia Study. Clin Pharmacol Ther 1994.
49:330, 1991. 198. Sharafuddin MJ, Spanheimer RG, McClune GL: Phenytoin-induced
173. Horowitz N, Molnar M, Levy Y, et al: Ramipril-induced agranulocyto- agranulocytosis: A nonimmunologic idiosyncratic reaction? Acta Hae-
sis confirmed by a lymphocyte cytotoxicity test. Am J Med Sci 329:52, matol 86:212, 1991.
2005. 199. Starkebaum G, Kenyon CM, Simrell CR, et al: Procainamide-induced
174. Jacquot C, Caudwell V, Belenfant X: Granulocytopenia after combined agranulocytosis differs serologically and clinically from procainamide-
therapy with interferon and angiotensin-converting enzyme inhibitors: induced lupus. Clin Immunol Immunopathol 78:112, 1996.
Evidence for a synergistic hematologic toxicity. Am J Med 101:235, 200. Ellrodt AG, Murata GH, Riedinger MS, et al: Severe neutropenia asso-
1996. ciated with sustained-release procainamide. Ann Intern Med 100:197,
175. Lee EJ, Kueh YK: Allopurinol—induced skin reactions and agranulo- 1984.
cytosis. Singapore Med J 23:178, 1982. 201. Velo GP, Milanino R: Nongastrointestinal adverse reactions to NSAID.
176. Scobie IN, MacCuish AC, Kesson CM, et al: Neutropenia during allo- J Rheumatol Suppl 20:42, 1990.
purinol treatment in total therapeutic starvation. Br Med J 280:1163, 202. Hopkinson ND, Saiz GF, Gumpel JM: Haematological side-effects
1980. of sulphasalazine in inflammatory arthritis. Br J Rheumatol 28:414,
177. Wilkinson DG: Allopurinol and agranulocytosis. Lancet 2:1282, 1977. 1989.
178. Hatton CS, Peto TE, Bunch C, et al: Frequency of severe neutropenia 203. Farr M, Symmons DP, Blake DR, et al: Neutropenia in patients with
associated with amodiaquine prophylaxis against malaria. Lancet 1:411, inflammatory arthritis treated with sulphasalazine. Ann Rheum Dis
1986. 45:761, 1986.
179. Ariad S, Hechtlinger V: Bezafibrate-induced neutropenia. Eur J Hae- 204. Levitt LJ: Chlorpropamide-induced pure white cell aplasia. Blood
matol 50:179, 1993. 69:394, 1987.
180. Nawabi IU, Ritz ND: Agranulocytosis due to propranolol. JAMA 205. Tucker SC, Lynch JP, Ansell BF, Jr: Chlorpropamide-induced agranu-
223:1376, 1973. locytosis. JAMA 238:422, 1977.